

Dated: 28th August, 2017

To,
Department of Corporate Service (DCS-CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001.

Sub: Submission of Un-audited Financial Results for the Quarter ended 30th June, 2017 in pursuance of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015.

Ref: NGL Fine-Chem Limited Scrip Code: 524774.

Dear Sir,


Kindly find attached herewith duly approved un-audited financial results for the quarter ended 30th June, 2017.

Kindly take on record and acknowledge the receipt of the same.

Thanking You,

Yours Faithfully,

For NGL Fine-Chem Limited.



Rahul Nachane
Managing Director
DIN: 00223346





MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110

2618 5137

Fax # 2618 4912

E-mail : manek@vsnl.com

shailesh.maneke@gmail.com

www.camaneke.com

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

LIMITED REVIEW REPORT OF THE AUDITORS

Review Report to,
The Board of Directors,
NGL Fine-Chem Limited

We have reviewed the accompanying statement of Unaudited Financial Results ('the Statement') of NGL Fine-Chem Limited ("the Company") for the quarter ended JUNE 30, 2017., prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initiated by us for the purpose of identification.

This statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee, at its meeting held on August 28, 2017, and , approved by the Board of Directors, at its meeting held on August 28, 2017.. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards, i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014- and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

MANEK & ASSOCIATES

We have not reviewed the accompanying unaudited financial results for the comparative period as of and for the quarter ended June 30, 2016 which have been presented solely based on information compiled by the management.

For MANEK & ASSOCIATES
Chartered Accountants
Firm's Registration No.:126679W



MUMBAI
DATED: 28/08/2017

SL Manek
(SHAILESH MANEK)
Proprietor
M.No.034925

**NGL FINE-CHEM LIMITED**

Regd Office: 301, E-Square

Subhash Road, Vile Parle (E), Mumbai-400057

CIN: L24110MH1981PLC025884

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017**PART I**

Rupees in lakhs

		Quarter ended	
		30.06.2017 (Unaudited)	30.06.2016 (Unaudited) Refer note 5
I	Revenue from Operations	2,313.14	2,501.79
II	Other Income	117.45	149.94
III	Total Revenue	2,430.59	2,651.73
IV	Expenses		
	a. Cost of materials consumed	995.16	912.93
	b. Purchase of Stock-in-Trade	6.74	49.10
	c. Changes in inventories of finished goods work-in-progress and stock-in-trade	(141.40)	1.99
	d. Excise Duty Paid	201.93	94.59
	e. Employee Benefit Expense	410.77	324.71
	f. Finance Cost	14.99	22.85
	g. Depreciation and Amortisation Expense	80.67	74.22
	h. Other Expenses	645.90	545.07
	i. Foreign Exchange Loss	2.91	-
	g. Total Expenses	2,217.67	2,025.46
V	Profit before exceptional items & tax (III-IV)	212.92	626.27
VI	Exceptional Items		
VII	Profit before tax [VII-VIII]	212.92	626.27
VIII	Tax Expense - Current Tax	(61.20)	(218.00)
	- Deferred Tax	8.33	4.21
	Total Tax Expenses (IV-V)	(52.87)	(213.79)
IX	Profit/(Loss) for the period from continuing operations [VII-VIII]	160.05	412.48
X	Profit/(Loss) from discontinuing operations before tax	-	-
XI	Tax Expenses of discontinuing operations	-	-
XII	Profit/(Loss) from discontinuing operations (after tax)	-	-
XIII	Total Profit (Loss) for the period [XI+XIV]	160.05	412.48
XIV	Other Comprehensive Income		
	Gain/(Loss) on actuarial valuation of post employment benefits	0.76	-2.93
	Deferred tax on above	-0.26	1.02
	Other Comprehensive Income (net of tax)	0.50	-1.91
XV	Total profit or loss, attributable to		
	Shareholders of the Company	160.05	412.48
	Non-controlling Interests	-	-
XVI	Total Comprehensive Income for the period attributable to		
	Shareholders of the Company	160.55	410.57
	Non-controlling Interests	-	-
	Details of Equity Share Capital		
	Paid-up Equity Share Capital	308.90	308.90
	Face Value of Equity Share Capital (Rupees per share)	5.00	5.00
XVII	Earnings per Equity Share of Rs. 10/- each		
	a) Basic	2.59	6.68
	b) Diluted	2.59	6.68

Notes:

- The above results have been reviewed by the Audit Committee, approved by the Board of Directors of the Company at its meeting held on August 28, 2017. The Statutory Auditors of the Company have carried out a "Limited Review" of the results for the quarter ended June 30, 2017.
- First time adoption of Ind AS:

The Company adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly, the transition was carried out, from the Accounting Principle's generally accepted in India as specified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 (previous GAAP), in accordance with Ind AS - 101 "First time adoption of Indian Accounting Standards". Accordingly, the impact of transition has been recorded in opening reserves as at April 1, 2016 and the periods presented have been restated accordingly.



NGL FINE-CHEM LIMITED

Regd Office: 301, E-Square

Subhash Road, Vile Parle (E), Mumbai-400057

CIN: L24110MH1981PLC025884

Reconciliation of net profit after tax reported in accordance with Indian GAAP to total comprehensive Income in accordance with Ind AS is given below

Sr. No.	Particulars	Note Number	Quarter ended 30 th June 2016
	Net Profit after tax as per Previous GAAP (Indian GAAP)		397.15
	Add/(-)Less:		
1	Impact of measuring Financial Investments at fair value through profit or loss (FVTPL)	a	22.03
2	Re-measurement of post-employment benefit obligations	b	2.93
3	Other Ind AS Adjustments		-9.63
	Total Ind AS adjustments		15.33
	Other comprehensive income (net of tax)		-1.91
	Total comprehensive income for the period		410.57

Notes:

a Fair Valuation of Financial Investments:

Under previous GAAP, Financial Investments were measured at transaction cost. Under Ind AS these financial investments have been classified as FVTPL on the date of transition and fair value changes after the date of transition has been recognized in the Statement of Profit and Loss.

b Re-measurement of post-employment benefit obligations:

Under Ind AS, re-measurements i.e. actuarial gains and losses and the return on plan assets, excluding amounts included in the net interest expenses on the net defined benefit liability, are recognized in other comprehensive income instead of profit or loss. Under the previous GAAP, these re-measurements were forming part of the profit or loss for the year.

3 The format for un-audited quarterly results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular CIR/CFD/FAC/62/2016 dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.

4 The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

5 The Ind AS financial results and financial information for the quarter ended June 30, 2016 have been compiled by the management after making necessary adjustments to give a true and fair view of the results. The information has not been subject to any Limited Review or audit.

6 There is a possibility that these Quarterly Financial Results may require adjustment before constituting the final Ind AS Financial Statements as at and for the year ending March 31, 2018, due to changes in financial reporting requirements arising from new or revised standards or interpretation issued by MCA/appropriate authority or changes in the use of one or more optional exemptions from full retrospective application of certain Ind AS as permitted under Ind AS-101.

7 The company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with Ind AS – 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rules 2015.

For and on behalf of the Board

Mumbai

28-Aug-17

Rahul Nachane

Managing Director